Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Jubilant HollisterStier, Lilly Enter Bamlanivimab Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Jubilant HollisterStier, Lilly Enter Bamlanivimab Mfg. Pact

COVID-19 therapy Bamlanivimab will be manufactured at Jubilant HollisterStier's Spokane, WA facility.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jubilant Life Sciences Ltd., an integrated global pharmaceuticals and life sciences company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through its contract manufacturing organization (CMO) subsidiary, Jubilant HollisterStier LLC, has signed a new contract with Eli Lilly for manufacturing of a treatment for COVID-19.
 
Lilly’s drug, Bamlanivimab, has been granted Emergency Use Authorization (EUA) by the FDA for emergency use as a treatment of COVID-19 and will be manufactured at Jubilant HollisterStier’s Spokane, WA facility.
 
“We are delighted to partner with our customers and contribute towards the fight against the COVID-19 pandemic,” said Pramod Yadav, chief executive officer, Jubilant Pharma Limited. “Our CMO business, an established player in the North American market, has strong capabilities in the manufacturing of sterile injectables—both liquid and lyophilization—and we are committed to continue exceeding expectations of our customers in this business.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics